To address the increasing pressure of liquid nitrogen storage management (refer to our previous three articles: "Global Incident Analysis of IVF Liquid Nitrogen Cryostorage Management", "Guardians of Life’s Temperature: A Complete Analysis of IVF Liquid Nitrogen Tank Monitoring Technology", and "Guardians of the Source of Life: Comprehensive Intelligent Monitoring of IVF Liquid Nitrogen Storage"), Fertsy Inc has designed and developed a new three-in-one AI monitoring system, CryoTrio™, within the existing equipment system and management processes of fertility centers.
The CryoTrio™ AI monitoring system has successfully obtained EU CE certification and US FCC certification, indicating that the system meets international standards in safety and reliability. CE certification is a mandatory safety certification imposed by the European Union on products entering its market. FCC certification is a market access credential for the United States, primarily focusing on the safety certification of wireless transmission equipment; products that have not obtained FCC certification are prohibited from being sold in the United States. The system employs wireless data transmission, avoiding cable constraints and minimizing the impact on daily laboratory operations. These certifications not only demonstrate that the system complies with the market access requirements of Europe and the United States but also reflect its high reliability and safety in medical environment applications.
The CryoTrio™ intelligent liquid nitrogen storage monitoring system is currently deployed and operating stably at IVF Canada Fertility Clinic Toronto and Aspire Houston Fertility Institute. These clinical practice cases validate the system’s applicability in the international high-end medical market.
CryoTrio™ liquid nitrogen storage monitoring system has successfully obtained CE/FCC international certification, signifying that the product has reached international leading standards in safety and reliability. This important milestone lays a solid foundation for the system’s entry into high-end medical markets in Europe and the United States. In the future, our company will continue to use innovative technology to safeguard every embryo and protect the birth of new life.